$0.46 Earnings Per Share Expected for Core Laboratories (NYSE:CLB) This Quarter

Equities analysts predict that Core Laboratories (NYSE:CLB) will announce earnings of $0.46 per share for the current quarter, according to Zacks Investment Research. Three analysts have issued estimates for Core Laboratories’ earnings, with the highest EPS estimate coming in at $0.47 and the lowest estimate coming in at $0.45. Core Laboratories posted earnings per share of $0.59 in the same quarter last year, which indicates a negative year over year growth rate of 22%. The company is scheduled to announce its next quarterly earnings results on Wednesday, July 24th.

On average, analysts expect that Core Laboratories will report full-year earnings of $1.97 per share for the current fiscal year, with EPS estimates ranging from $1.84 to $2.15. For the next fiscal year, analysts forecast that the company will post earnings of $2.60 per share, with EPS estimates ranging from $2.43 to $2.85. Zacks’ earnings per share calculations are an average based on a survey of sell-side analysts that cover Core Laboratories.

Core Laboratories (NYSE:CLB) last posted its quarterly earnings results on Wednesday, April 24th. The oil and gas company reported $0.44 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.43 by $0.01. The firm had revenue of $169.19 million during the quarter, compared to analyst estimates of $166.79 million. Core Laboratories had a return on equity of 57.13% and a net margin of 13.79%. Core Laboratories’s quarterly revenue was down .5% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.57 EPS.

Several research firms have recently issued reports on CLB. Zacks Investment Research lowered Core Laboratories from a “buy” rating to a “hold” rating in a research report on Friday, April 26th. Tudor Pickering raised Core Laboratories from a “hold” rating to a “buy” rating in a research report on Monday, February 25th. Finally, Stifel Nicolaus set a $75.00 target price on Core Laboratories and gave the stock a “buy” rating in a research report on Friday, April 26th. Two analysts have rated the stock with a sell rating, nine have given a hold rating and six have assigned a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average price target of $86.45.

CLB opened at $48.96 on Thursday. The company has a quick ratio of 1.45, a current ratio of 1.84 and a debt-to-equity ratio of 1.92. The stock has a market capitalization of $2.17 billion, a PE ratio of 22.77, a P/E/G ratio of 1.92 and a beta of 1.95. Core Laboratories has a 1 year low of $46.32 and a 1 year high of $129.43.

The firm also recently announced a quarterly dividend, which was paid on Tuesday, May 21st. Shareholders of record on Friday, April 26th were given a $0.55 dividend. This represents a $2.20 dividend on an annualized basis and a yield of 4.49%. The ex-dividend date of this dividend was Thursday, April 25th.

In other Core Laboratories news, CAO Kevin Daniels sold 428 shares of the business’s stock in a transaction dated Monday, March 11th. The stock was sold at an average price of $66.25, for a total value of $28,355.00. Following the completion of the transaction, the chief accounting officer now owns 352 shares of the company’s stock, valued at approximately $23,320. The sale was disclosed in a legal filing with the SEC, which is available through this link. 2.00% of the stock is currently owned by insiders.

Institutional investors have recently added to or reduced their stakes in the business. Millennium Management LLC grew its stake in shares of Core Laboratories by 277.4% during the 4th quarter. Millennium Management LLC now owns 797,161 shares of the oil and gas company’s stock valued at $47,559,000 after purchasing an additional 585,945 shares during the period. Triangle Securities Wealth Management bought a new stake in shares of Core Laboratories during the 1st quarter valued at about $483,000. Vanguard Group Inc grew its stake in shares of Core Laboratories by 1.7% during the 3rd quarter. Vanguard Group Inc now owns 3,895,451 shares of the oil and gas company’s stock valued at $451,209,000 after purchasing an additional 64,032 shares during the period. Eqis Capital Management Inc. grew its stake in shares of Core Laboratories by 23.4% during the 1st quarter. Eqis Capital Management Inc. now owns 9,655 shares of the oil and gas company’s stock valued at $666,000 after purchasing an additional 1,832 shares during the period. Finally, BNP Paribas Arbitrage SA grew its stake in shares of Core Laboratories by 428.1% during the 1st quarter. BNP Paribas Arbitrage SA now owns 37,962 shares of the oil and gas company’s stock valued at $2,617,000 after purchasing an additional 30,773 shares during the period.

Core Laboratories Company Profile

Core Laboratories N.V. provides reservoir description and production enhancement services and products to the oil and gas industry in the United States, Canada, and internationally. The company operates in two segments, Reservoir Description and Production Enhancement segments. The Reservoir Description segment includes the characterization of petroleum reservoir rock, fluid, and gas samples to enhance production and improve recovery of oil and gas from its clients' reservoirs.

Further Reading: What are Bollinger Bands?

Get a free copy of the Zacks research report on Core Laboratories (CLB)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Core Laboratories (NYSE:CLB)

Receive News & Ratings for Core Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Core Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.